The Pharmacy Times® Dermatology Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of skin disorders, including psoriasis, atopic dermatitis, eczema, and acne.
February 2nd 2023
Results from the phase 2 and long-term trials will be presented later this year, following further data collection.
Phase 3 Data Favor Bimekizumab Over Placebo in Biologic-Naïve Patients With Psoriatic Arthritis
December 20th 2022All primary and ranked secondary endpoints of the study were met at week 16, which were sustained or improved through week 24 and were coupled with patient-reported improvements compared with placebo in treating psoriatic arthritis.
Read More
Lebrikuzumab Found to Maintain Durable Skin Clearance When Dosed Every 4 Weeks in Atopic Dermatitis
September 14th 2022ADvocate 1 and ADvocate 2 are 52-week randomized, double-blind phase 3 studies designed to evaluate lebrikizumab as monotherapy in adult and adolescent patients with moderate to severe AD.
Read More
FDA Approves Citrate-Free High-Concentration Humira Biosimilar Hadlima
August 18th 2022Adalimumab-bwwd is a tumor necrosis factor blocker indicated for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, and plaque psoriasis.
Read More